A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study

In this phase III study, metastatic breast cancer patients who had had a response on first-line taxane and bevacizumab treatment were randomized to continue on this regimen or to receive endocrine therapy plus bevacizumab. We failed to show superior efficacy of the endocrine treatment maintenance strategy compared with the continuation of the treatment that have achieved initial tumor control.

from Cancer via ola Kala on Inoreader http://ift.tt/24spaZl
via IFTTT